Anne Cambon-Thomsen

Anne Cambon-Thomsen

Auto-generated profile, based on publicly available information

Anne Cambon-Thomsen

Institut National de la Santé et de la Recherche Médicale, France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2007 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
ACA. Cambon-Thomsen
A. Cambon-Thomsen
ERE. Rial-Sebbag
E. Rial-Sebbag
BKB. M. Knoppers
B. M. Knoppers
Numerous studies of genetic epidemiology and post-genomics in respiratory diseases rely on the use of biobanks, defined as organised biological sample collections with associated personal and clinical data. The use of biobanks is increasing and raises several ethical issues. What are the ethical trends and legal frameworks in the post-genomic era? Are there new issues in relation to the developments of techniques and new study designs? How does this affect the clinician’s attitudes and relationship with the patients?The main ethical issues encountered are: informed consent; confidentiality; secondary use of samples and data over time; return of results; and data sharing. Different levels and modalities of dealing with such issues are identified and vary from legally binding measures to “soft” regulations, such as ethical recommendations by various committees or professional organisations.A further level of complexity appears with the increasing international dimension of such activities in a context in which national positions vary on those topics. There is a tension between a necessary level of diversity in ethical positions and an indispensable common pedestal of principles and procedures to manage these issues in order to foster research.Current legal and ethical trends favour the facilitation of secondary use of samples, more biobank openness, balanced with a growing attention to dialogue and public/stakeholder consultation, an increased role for research ethics committees and more sophisticated data protection and governance structures.

1 November 2004 in Nature Reviews Genetics
Verified
Journal Article
Closed access
ACAnne Cambon-Thomsen
Anne Cambon-Thomsen

1 January 2011 in Genome Medicine
Verified
Journal Article
Open access
PDF file
PBPhilippe Jean Bousquet
Philippe Jean Bousquet
JAJosep M Anto
Josep M Anto
PSPeter J Sterk
Peter J Sterk
IAIan Adcock
Ian Adcock
KCKian Chung
Kian Chung
CACharles Auffray
Charles Auffray
We propose an innovative, integrated, cost-effective health system to combat major non-communicable diseases (NCDs), including cardiovascular, chronic respiratory, metabolic, rheumatologic and neurologic disorders and cancers, which together are the predominant health problem of the 21st century. This proposed holistic strategy involves comprehensive patient-centered integrated care and multi-scale, multi-modal and multi-level systems approaches to tackle NCDs as a common group of diseases. Rather than studying each disease individually, it will take into account their intertwined gene-environment, socio-economic interactions and co-morbidities that lead to individual-specific complex phenotypes. It will implement a road map for predictive, preventive, personalized and participatory (P4) medicine based on a robust and extensive knowledge management infrastructure that contains individual patient information. It will be supported by strategic partnerships involving all stakeholders, including general practitioners associated with patient-centered care. This systems medicine strategy, which will take a holistic approach to disease, is designed to allow the results to be used globally, taking into account the needs and specificities of local economies and health systems.

28 May 2003 in European Journal of Human Genetics
Verified
Journal Article
Closed access
OCon behalf of the EUROGENBANK consortium**
on behalf of the EUROGENBANK consortium**
IHIsabelle Hirtzlin
Isabelle Hirtzlin
CDChristine Dubreuil
Christine Dubreuil
NPNathalie Préaubert
Nathalie Préaubert
JDJenny Duchier
Jenny Duchier
ACAnne Cambon-Thomsen
Anne Cambon-Thomsen

1 May 2003 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ACAnne Cambon-Thomsen
Anne Cambon-Thomsen

1 June 2000 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
AFA Foissac
A Foissac
MSM. Salhi
M. Salhi
ACA. Cambon-Thomsen
A. Cambon-Thomsen